Could CD47 Competitors Catch Up To Gilead After Magrolimab Hold?

 
• By Alaric DeArment

Gilead isn’t giving details about the events behind the partial hold on magrolimab/Vidaza combination studies, but analysts suspect cytopenias are the culprit.

Cancer cells on scientific background.3d illustration
Gilead said the FDA had placed a partial hold on its trials testing magrolimab with Vidaza • Source: Shutterstock

More from Clinical Trials

More from R&D